Research Analysts Offer Predictions for CADL Q2 Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Equities researchers at Brookline Capital Management issued their Q2 2025 earnings estimates for shares of Candel Therapeutics in a research report issued on Wednesday, July 9th. Brookline Capital Management analyst K. Dolliver expects that the company will earn ($0.18) per share for the quarter. Brookline Capital Management has a "Strong-Buy" rating on the stock. The consensus estimate for Candel Therapeutics' current full-year earnings is ($1.47) per share. Brookline Capital Management also issued estimates for Candel Therapeutics' Q3 2025 earnings at ($0.21) EPS and Q4 2025 earnings at ($0.23) EPS.

Several other equities analysts have also recently commented on CADL. HC Wainwright raised shares of Candel Therapeutics to a "buy" rating and set a $23.00 price target on the stock in a research report on Monday, June 30th. Wall Street Zen raised shares of Candel Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $22.00.

Candel Therapeutics Stock Performance

NASDAQ:CADL opened at $5.81 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.64 and a quick ratio of 4.64. The firm has a 50-day moving average of $5.29 and a two-hundred day moving average of $6.58. The stock has a market cap of $291.10 million, a P/E ratio of -4.34 and a beta of -0.91. Candel Therapeutics has a 1-year low of $3.79 and a 1-year high of $14.60.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported $0.13 earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.37.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CADL. Baker BROS. Advisors LP acquired a new position in shares of Candel Therapeutics during the fourth quarter valued at approximately $25,884,000. Acorn Capital Advisors LLC acquired a new position in shares of Candel Therapeutics during the fourth quarter valued at approximately $16,836,000. Braidwell LP acquired a new position in shares of Candel Therapeutics during the fourth quarter valued at approximately $13,888,000. Portolan Capital Management LLC acquired a new position in shares of Candel Therapeutics during the fourth quarter valued at approximately $6,543,000. Finally, Halter Ferguson Financial Inc. increased its stake in shares of Candel Therapeutics by 123.7% during the fourth quarter. Halter Ferguson Financial Inc. now owns 681,334 shares of the company's stock valued at $5,914,000 after acquiring an additional 376,795 shares during the period. Institutional investors and hedge funds own 13.93% of the company's stock.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.